TAIPEI, Taiwan, December 12, 2025 –TaiGen Biotechnology Company, Limited (“TaiGen”) today announced that it, together with its wholly-owned Beijing subsidiary TaiGen Biopharmaceuticals ,has entered into an exclusive in-licensing agreement with Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company. Under the terms of the agreement, TaiGen was granted the exclusive rights for further development, commercialization, and sub-licensing in the Greater China area, including Mainland China, Hong Kong, Macau, and Taiwan, of ISM4808, a PHD inhibitor, and its related forms and structures.

ISM4808, a promising AI-driven candidate, is a potential best-in-class PHD inhibitor that targets the Nobel-winning HIF-α pathway for the treatment of anemia of chronic kidney disease (CKD), through Erythropoietin (EPO) induction and iron utilization improvement for better blood cell replacement.

Notably, the novel structure of ISM4808 was empowered by Insilico’s proprietary Chemistry42 engine and was designed, synthesized, and tested within a 12-month window. The discovery journey of ISM4808 series was published in the Journal of Medicinal Chemistry in January 2024.

In preclinical studies, ISM4808 showed compelling potency across in vitro and in vivo assays, along with promising oral drug-like properties and safety profiles. The program received IND clearance from China’s CDE in 2023.

“We are pleased to enter this strategic partnership with Insilico Medicine. The innovation Insilico brings through its generative AI platform is truly impressive.” said Kuo-Lung Huang, Chairman of TaiGen Biotechnology. “With over a million dialysis patients in Mainland China, the PHD inhibitor market is experiencing explosive growth, having surged from approximately 50 million RMB to 2.45 billion RMB in just 5 years. As oral drugs progressively replace traditional injectables, TaiGen is dedicated to advancing this innovative program to meet the urgent clinical need for convenient and compliant therapies.”

“Powered by AI, Insilico has efficiently nominated two novel PHD inhibitors for different indications,” said Feng Ren, PhD, Co-CEO and CSO of Insilico Medicine. “We are pleased that one of them, ISM4808, will be advanced by our partner TaiGen, a well-established biopharma company. I believe TaiGen’s strong drug development capabilities and clinical resources will help accelerate the program and bring AI-driven therapies to patients worldwide sooner.”

Anemia associated with Chronic Kidney Disease is a serious global health issue, accounting for over 1.5 million deaths annually. Furthermore, more than one in seven people with CKD have anemia. In patients with CKD, the kidneys produce less EPO, leading to insufficient red blood cell production. Currently, anemia cannot be totally cured, and existing treatments, which focus on relieving symptoms like fatigue and shortness of breath, highlight a significant unmet medical need.

About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

About TaiGen Biotechnology
Founded in 2001 and listed on the Taiwan OTC Market in 2014, TaiGen Biotechnology is a fully integrated pharmaceutical company focused on innovative small-molecule drugs, particularly anti-infectives. The company has expertise in drug discovery, development, regulatory approval, and multi-country clinical trials, with experience in overseas licensing. Its flagship antibiotic, Taigexyn® (Nemonoxacin), is approved in Taiwan, China, and Russia, while the influenza antiviral TG-1000 has completed Phase III trials and filed an NDA in China.